UK Markets closed

Celsion Corporation (CLSN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.7310+0.0123 (+1.71%)
At close: 4:00PM EDT

0.7650 +0.03 (4.65%)
After hours: 7:59PM EDT

Sign in to post a message.
  • B
    Big fish
    It may be whacky but I don’t think the Thermodox story is done. It’s too weird that all the studies, prior NIH study, earlier results, early readout, and analysis could all be wrong. It’s logical that Thermodox should deliver. 26 deaths suddenly ? They have cash, a supporting long term investor. ,and the Gen 2 so it’s worth a shot.
    26 patients? And the crazy 90.
  • R
    Roland
    Some pretty good news this morning. No warrant financing above current share price, progress on studies...any other stock and it would be up lol.
  • G
    Good Guy
    I have an idea, big toe. Move on. There will be many times you take the loss.
  • m
    madqed
    "In consideration for LPC entering into the purchase agreement, Celsion issued shares of its common stock to LPC as a fee for LPC’s obligation to purchase shares at the Company’s discretion." So, how many shares did CLSN issue to LPC? I'm thinking it was more than enough to offset the 28% premium.
  • P
    Pierre
    Seriously time to look for merger and/or straight buy out.
    Big boys are looking again and for sure, CLSN has lost all momentum to do it alone
    THERMODOX technology makes sense but needs big pharms energy/experience/talents to make it happen
  • B
    Bitrunner
    When the issues with China and Vietnam patients are resolved, and the FDA reviews all the data, and finds plenty of reasons to push forward with this treatment, will the stock rocket up like an elon musk rocket, or will investors only remember their losses? Or, assuming FDA or European approval, will investors wait for revenues to show up before investing?
  • A
    American Patriot
    lol i should have sold at $5. My cost basis is $2.41. Would've made a nice profit. Thank god I only have 500 shares. Not selling. Keeping it as a lotto ticket. You never know. They are not dead yet.
  • B
    Big Toe
    Whens the next reverse?
  • m
    madqed
    Data Maturity issue? I've been considering how they ended up with 26 consecutive events from the treatment arm. If T'dox has no effect, either positive or negative, on treatment outcome we could treat these events as outcomes from consecutive flips of a fair coin, considering an event from the treatment arm as a "heads" and an event from the control arm as a "tails. There are some caveats to this however. Unlike flips of a coin, the outcomes from either group reduces the possible number, and thus the odds, for another outcome from that group. when flipping a coin a "heads" result doesn't reduce the possible number of future "heads". Also, the population of treatment arm patients would have been greater at the beginning of the 26 event run. As the run of 26drew near the end, the numbers of patients in each arm would have been more nearly but not exactly equal. The p values indicate the degree of this inequality. I don't care enough to try to find the exact number in each arm and do the more complex calculation taking into account the steadily reducing number in treatment arm as the 26 consecutive events played out. However, calculating the odds for 26 consecutive identical results, when only 2 results are equally possible I come up with a 1 in 68,108,864. If you skew the probabilities to account for the unequal numbers in each arm and assign a 55% chance of an event from the treatment arm at each event, the odds become 1 in 5,630,800. Remember, this is assuming that T'dox has no positive value. I believe that something other than data immaturity is at work here.
  • m
    madqed
    If anyone believes that LPC bought $1M worth at a 28% premium without a behind the back sweetheart deal, you don't know CLN and it's management.
  • B
    Bil
    List of shame:
    Name Title Pay Exercised Year Born
    Mr. Michael H. Tardugno Exec. Chairman, Pres & CEO 786.91k N/A 1951
    Mr. Jeffrey W. Church CPA, CPA CFO, Exec. VP & Corp. Sec. 455.92k N/A 1957
    Dr. Khursheed Anwer Exec. VP & Chief Scientific Officer 409.32k N/A 1960
    Dr. Nicholas Borys Exec. VP & Chief Medical Officer 505.98k N/A 1959
    Mr. Timothy J. Tumminello Chief Accounting Officer & Controller N/A N/A 1958

    Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options
  • B
    Big Toe
    I have an idea..Why doesn't management take some of that dilution money and buy some shares in the open market?
  • A
    Anonymous
    This is from 2013, unfortunately, this looks so similar. "The failure of ThermoDox in the phase III Heat trial is a catastrophe with serious implications for Celsion, something now reflected in the biotech’s shares, which plunged by 81% Thursday. With ThermoDox being investigated in five other types of cancer, and Celsion’s other two early-stage programmes based on the same liposomal encapsulation technology as ThermoDox, the company’s future looks bleak. The company is now contemplating its options. It says it will decide shortly whether to follow the Heat patients to determine whether ThermoDox improves overall survival. Further analyses, including subgroup research, would also be conducted, Mr Tardugno said. No decisions have yet been made regarding the phase II trials assessing ThermoDox in breast cancer, osteosarcoma, lung cancer and colon cancer liver metastasis."
    Where is the reassessment at present?
  • S
    Samson
    Ovarian Cancer Treatment: Our last hope. Hope it passes the phase in clinical trial.
  • m
    madqed
    This cash cow will look like a deflated balloon by the time MT and company are done with it. What prospects for success do they have? Optima has virtually no chance of success now. Will they massage the data to come up with a new subgroup for a new trial? That would take another 8 years. How about the GEN 1 OVATION study? That is projected to be completed 2 years from now. The problem is, that is only a phase 2 study and not a pivotal study. So, at least 10 years before they could file for an NDA, IF all goes well (when has that ever happened for this group? So, MT and group will continue to rearrange the deck chairs on the Titanic like they can prevent it from sinking, all the time sucking as much money out of the company as they can. Stick a fork in it.
  • A
    Anonymous
    Wow, this management has nothing to say anymore and has no power. The others take control and know that CLSN with this management has no future.
    Read this part of todays news:

    "Celsion issued to Horizon warrants exercisable into 247,525 shares of Celsion’s common share at an exercise price of $1.01 per share. Warrants previously issued to Horizon exercisable into 95,057 shares at an exercise price of $2.63 per share were cancelled."

    Not "were" cancelled but Horizon cancelled it! Read between the lines.

    Management is still talking about support and belief. Sorry, but not a single person believe you anymore!!! Bye bye
  • J
    Juan
    Big toe. Still here bashing cuz you lost $200?
  • B
    Big Toe
    Down a little at a time until it's all gone
  • C
    Chrisariel
    Tomorrow morning we will:
    Rejoice or Regret
  • j
    joe
    So my 5600 investment is worth 300 bucks. I will use this as a write off and lesson learned.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more